Major Korro Bio (KRRO) holder adds shares and pre-funded warrants

Rhea-AI Filing Summary

Korro Bio, Inc. reported that investment entity New Enterprise Associates 17, L.P. acquired additional exposure to its stock through a private subscription. On March 10, 2026, it bought 207,100 shares of common stock at $11.11 per share and 242,945 pre-funded warrants at $11.109 per warrant. The warrants are exercisable at $0.001 per share but include a 9.99% beneficial ownership cap, which the holder may adjust upon 61 days’ notice, not to exceed 19.99%. Following these purchases, indirect holdings include 1,297,893 shares of common stock and the newly acquired warrants. Forest Baskett is a manager of entities controlling NEA 17 and disclaims beneficial ownership where he has no pecuniary interest.

Insider Trade Summary

Net Buyer: 450,045 shares ($4,999,757)

Net Buy 2 txns

Insider BASKETT FOREST

Role 10% Owner

Bought 450,045 shs ($5.00M)

Type	Security	Shares	Price	Value
Purchase	Pre-Funded Warrants	242,945	$11.109	$2.70M
Purchase	Common Stock	207,100	$11.11	$2.30M

Holdings After Transaction: Pre-Funded Warrants — 242,945 shares (Indirect, See Note 2); Common Stock — 1,297,893 shares (Indirect, See Note 2)

Footnotes (1)

1. Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BASKETT FOREST

(Last) (First) (Middle)

2855 SAND HILL ROAD

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		P(1)		207,100	A	$11.11	1,297,893	I	See Note 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrants	$0.001	03/10/2026		P(1)		242,945		(3)	(3)	Common Stock	242,945	$11.109	242,945	I	See Note 2(2)

Explanation of Responses:

1. Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.

2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

3. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

	/s/ Zachary Bambach, attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Korro Bio (KRRO) disclose in this Form 4?

Korro Bio disclosed that New Enterprise Associates 17, L.P. indirectly bought 207,100 common shares and 242,945 pre-funded warrants on March 10, 2026. Both purchases were open-market or private transactions under a subscription agreement, increasing the holder’s overall economic exposure.

How many Korro Bio (KRRO) shares does the reporting group hold after these trades?

After the transactions, the reporting group indirectly holds 1,297,893 shares of Korro Bio common stock. It also owns 242,945 pre-funded warrants, each exercisable into one common share, further increasing potential future ownership subject to stated beneficial ownership limitations.

What are the key terms of the pre-funded warrants bought in Korro Bio (KRRO)?

The pre-funded warrants cover 242,945 Korro Bio shares and are exercisable at $0.001 per share. They are exercisable at any time after issuance but are subject to a 9.99% ownership cap, adjustable up to 19.99% with 61 days’ prior notice.

At what prices were Korro Bio (KRRO) securities acquired in this Form 4?

The group paid $11.11 per share for 207,100 Korro Bio common shares and $11.109 per pre-funded warrant for 242,945 warrants. Each warrant is later exercisable at a nominal $0.001 per underlying common share, subject to beneficial ownership limits.

Who is the actual holder of the Korro Bio (KRRO) securities in this filing?

The direct beneficial owner is New Enterprise Associates 17, L.P.. Forest Baskett is a manager of entities that control NEA 17 but disclaims beneficial ownership of portions of the securities in which he has no pecuniary interest, consistent with Section 16 guidance.

How were the Korro Bio (KRRO) pre-funded warrants and shares acquired?

Both the pre-funded warrants and common shares were acquired from Korro Bio pursuant to a Subscription Agreement dated March 9, 2026. Settlement occurred on March 10, 2026, reflecting a negotiated investment rather than ordinary secondary-market trading activity.